Latest Articles

Publication Date
A Multifunctional Molecular Probe for Multimodal Imaging-Guided Potent Photothermal/Photodynamic Therapy of Endometriosis.

Multifunctional small-molecule theranostic agents hold significant clinical potential for non-invasive endometriosis (EMS) management. Current EMS treatment faces challenges due to imprecise lesion localization and therapy-associated side effects. Herein, an integrated …

Published: Aug. 28, 2025, midnight
Feasibility, acceptability, and exploratory outcomes of a virtual cognitive behavioural therapy-based group intervention for persistent fatigue in endometriosis: The Managing Fatigue in Endometriosis (MEND) programme.

This study developed and assessed the feasibility, acceptability, and exploratory outcomes of a six-session cognitive behavioural therapy (CBT)-based intervention for endometriosis-related persistent fatigue, called Managing Fatigue in Endometriosis (MEND).

Published: Aug. 27, 2025, 12:01 a.m.
Emerging Mechanisms of NK Cell Dysfunction in Endometriosis: The Role of Autophagy, Metabolism, Cytokines, Exosomes, and Trogocytosis.

Endometriosis (EMS) is a persistent, inflammatory condition that relies on estrogen and is distinguished by the proliferation of endometrial tissue outside the confines of the uterus. The impact on the …

Published: Aug. 27, 2025, 12:01 a.m.
Nanotechnology strategies for endometrium health: Are we on the right track?

The endometrium is a vital mucosal tissue which undergoes cyclical regeneration, differentiation, and remodeling upon hormonal, cellular, and molecular signaling networks. Dysregulation of these processes can trigger a range of …

Published: Aug. 27, 2025, midnight
Metastatic Carcinomas at the Episiotomy Site: A Systematic Literature Review.

Background/Objectives: Rarely, primary (PriCs) or metastatic (metECs) carcinomas occur in the episiotomy site. Methods: A systematic literature review of metECs was carried out. We reviewed the PRISMA guidelines and the …

Published: Aug. 27, 2025, midnight
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer - CancerNetwork

Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer CancerNetwork

Published: Aug. 26, 2025, 10:07 p.m.
FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer - Targeted Oncology

FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer Targeted Oncology

Published: Aug. 26, 2025, 6:30 p.m.
Rina-S Given Breakthrough Therapy Designation in Endometrial Cancer - Oncology Nursing News

Rina-S Given Breakthrough Therapy Designation in Endometrial Cancer Oncology Nursing News

Published: Aug. 26, 2025, 6:04 p.m.
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced - PharmiWeb.com

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced PharmiWeb.com

Published: Aug. 26, 2025, 4:10 p.m.
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer - OncLive

Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer OncLive

Published: Aug. 26, 2025, 3:01 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!